Zevra Therapeutics
ZVRA
84 hedge funds and large institutions have $83M invested in Zevra Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 35 increasing their positions, 11 reducing their positions, and 7 closing their positions.
218% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
60% more capital invested
Capital invested by funds: $52.1M → $83M (+$31M)
9% more funds holding
Funds holding: 77 → 84 (+7)
0.57% less ownership
Funds ownership: 31.82% → 31.25% (-0.57%)
44% less call options, than puts
Call options by funds: $1.19M | Put options by funds: $2.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.53M |
| 2 |
AC
Armistice Capital
New York
|
+$1.25M |
| 3 |
BlackRock
New York
|
+$1.22M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$782K |
| 5 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$679K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$212K |
| 2 |
LCM
Laurion Capital Management
New York
|
-$150K |
| 3 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$109K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$52K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$48.1K |
ZVRA Hedge Fund Activity: Q4 2023 in Review
84 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Zevra Therapeutics (ZVRA) for Q4 2023, worth a combined $83M — up 60% from $52.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new ZVRA positions and 7 closed out — a net gain of 7 holders — while 35 added to existing stakes and 11 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $2.53M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $212K.
- 84 institutional investors held Zevra Therapeutics (ZVRA) as of Q4 2023, up from 77 in Q3 2023.
- Funds reported $83M of Zevra Therapeutics stock for Q4 2023, up 60% quarter-over-quarter.
- 14 funds opened new Zevra Therapeutics positions in Q4 2023 and 7 closed out, a net change of +7 holders.
- The largest Zevra Therapeutics buyer in Q4 2023 was 683 Capital Management, an estimated $2.53M added.
- The largest Zevra Therapeutics seller in Q4 2023 was Jacobs Levy Equity Management, an estimated $212K sold.
Based on aggregated 13F filings for Q4 2023.